Literature DB >> 16464193

Meeting the NICE requirements: a Markov model approach.

J Mauskopf1.   

Abstract

The National Institute of Clinical Excellence (NICE) was established in the United Kingdom in April 1999 to issue guidance for the National Health Service (NHS) on the use of selective new health care interventions. This article describes the NICE requirements for both incidence-based cost-effectiveness analyses and prevalence-based estimates of the aggregate NHS impact of the new drug. The article demonstrates how both of these requirements can be met using Markov modeling techniques. A Markov model for a hypothetical new treatment for HIV infection is used as an illustration of how to generate the estimates that are required by NICE. The article concludes with a discussion of the difficulties of obtaining data of sufficient quality to include in the Markov model to ensure that the submission meets all the NICE requirements and is credible to the NICE advisory board.

Entities:  

Year:  2000        PMID: 16464193     DOI: 10.1046/j.1524-4733.2000.34006.x

Source DB:  PubMed          Journal:  Value Health        ISSN: 1098-3015            Impact factor:   5.725


  6 in total

1.  Population- versus cohort-based modelling approaches.

Authors:  Olivier Ethgen; Baudouin Standaert
Journal:  Pharmacoeconomics       Date:  2012-03       Impact factor: 4.981

Review 2.  A review of economic evaluations of darunavir boosted by low-dose ritonavir in treatment-experienced persons living with HIV infection.

Authors:  Josephine Mauskopf; Lieven Annemans; Andrew M Hill; Erik Smets
Journal:  Pharmacoeconomics       Date:  2010       Impact factor: 4.981

Review 3.  A Methodological Review of US Budget-Impact Models for New Drugs.

Authors:  Josephine Mauskopf; Stephanie Earnshaw
Journal:  Pharmacoeconomics       Date:  2016-11       Impact factor: 4.981

4.  Cost-effectiveness of new adult pneumococcal vaccination strategies in Italy.

Authors:  Sara Boccalini; Angela Bechini; Miriam Levi; Emila Tiscione; Roberto Gasparini; Paolo Bonanni
Journal:  Hum Vaccin Immunother       Date:  2013-01-07       Impact factor: 3.452

5.  Cost-effectiveness analysis of Option B+ for HIV prevention and treatment of mothers and children in Malawi.

Authors:  Olufunke Fasawe; Carlos Avila; Nathan Shaffer; Erik Schouten; Frank Chimbwandira; David Hoos; Olive Nakakeeto; Paul De Lay
Journal:  PLoS One       Date:  2013-03-12       Impact factor: 3.240

6.  A randomized controlled trial studying the effectiveness of group medical appointments on self-efficacy and adherence in sickle cell disease (TEAM study): study protocol.

Authors:  Marlous J Madderom; Jessica Heijdra; Elisabeth M W J Utens; Suzanne Polinder; Anita W Rijneveld; Marjon H Cnossen
Journal:  BMC Hematol       Date:  2016-08-04
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.